{"id":522333,"date":"2021-08-03T16:03:15","date_gmt":"2021-08-03T20:03:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-reports-second-quarter-2021-financial-results\/"},"modified":"2021-08-03T16:03:15","modified_gmt":"2021-08-03T20:03:15","slug":"curis-reports-second-quarter-2021-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-reports-second-quarter-2021-financial-results\/","title":{"rendered":"Curis Reports Second Quarter 2021 Financial Results"},"content":{"rendered":"
\n

– Presented positive updated data from Phase 1\/2 study of CA-4948 monotherapy in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) at the European Hematology Association 2021 Virtual Congress (EHA) –<\/h2>\n

– Clear anticancer activity observed in molecularly-enriched AML\/MDS population with spliceosome or FLT3 mutations; 4 of 4 evaluable patients (100%) achieved objective response –<\/h2>\n

– Further anticancer activity also observed in a broader population of AML\/MDS patients; 9 of 11 evaluable patients (82%) achieved marrow blast reductions or maintenance of blast level for patients in the normal range at baseline –<\/h2>\n

– Additional clinical data expected by year-end in AML\/MDS patients with SF3B1 and U2AF1 spliceosome mutations –<\/h2>\n

– Management to host conference call today at 4:30 p.m. ET –<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n LEXINGTON, Mass.<\/span>, Aug. 3, 2021<\/span> \/PRNewswire\/ —\u00a0Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2021<\/span>.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/Curis,
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“In the second quarter of 2021, we continued executing on planned milestones across our pipeline of next generation targeted cancer therapies designed to meaningfully improve and extend patients’ lives. We drove important progress with\u00a0our first-in-class, small molecule IRAK4 inhibitor CA-4948, expanding our clinical trials into nine distinct patient populations across AML\/MDS and B cell cancers. In June, we presented updated data from our Phase 1\/2 relapsed\/refractory (R\/R) AML\/MDS study at EHA, which showcased continued improvements in clinical activity and robust tolerability in extremely fragile patients,” said James Dentzer<\/span>, President and Chief Executive Officer of Curis.\u00a0“At the 300mg BID dose we are seeing clear anticancer activity and are achieving pharmacokinetic (PK) exposure in patients that correlates to 98% inhibition in preclinical models. In addition, we are encouraged by a predictable and manageable safety profile with no dose-limiting toxicities related to myelosuppression and no overlapping dose-limiting toxicities with existing anticancer therapies planned for dosing in combination with CA-4948. The data at EHA also highlighted that we have identified a subset of patients with specific mutations that may make their disease highly amenable to CA-4948 monotherapy; all 4 of 4 evaluable patients with spliceosome or FLT3 mutations experienced an objective response. With further expansion of this group of patients, we may be able to identify a rapid path to regulatory approval for CA-4948. We also reported that even in patients without these specific mutations, CA-4948 demonstrated consistent tumor burden reduction, providing opportunities for combination development in a broader population. We expect to begin enrolling patients later this year in combination therapy evaluating CA-4948 with azacitidine or venetoclax. In total, we are exploring CA-4948 in four distinct cohorts in AML\/MDS in addition to lower risk MDS, which is the subject of a separate Investigator Sponsored Trial (the LUCAS IST). We are also exploring CA-4948 in combination with ibrutinib across four additional cohorts in B cell cancers.” <\/p>\n

Mr. Dentzer added, “Lastly, we are also pleased with the continuing dose escalation in our ongoing Phase 1 study of CI-8993, our first-in-class monoclonal anti-VISTA antibody for the treatment of patients with R\/R solid tumors. <\/p>\n

“We look forward to providing an update on enrollment progress for all studies, including data updates for the spliceosome cohort in AML\/MDS and the VISTA study, later this year.”\u00a0 <\/p>\n

\n Second Quarter 2021 and Recent Operational Highlights<\/b>\n <\/p>\n

\n Precision oncology, CA-4948 (IRAK4 Inhibitor; Aurigene collaboration):<\/b>\n <\/p>\n